03/20/2024 3:10 PM | Fulcrum Therapeutics (Issuer) Horn Patrick Taylor (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
03/20/2024 3:15 PM | Fulcrum Therapeutics (Issuer) Horn Patrick Taylor (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/08/2024 5:00 PM | Fulcrum Therapeutics (Subject) Tourangeau Greg (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/08/2024 5:05 PM | Fulcrum Therapeutics (Issuer) Tourangeau Greg (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/27/2024 6:01 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/14/2024 6:53 AM | Fulcrum Therapeutics (Subject) RTW INVESTMENTS, LP (Filed by)
| Form SC 13G/A | |
02/13/2024 11:08 AM | Fulcrum Therapeutics (Subject) SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
|
02/07/2024 6:44 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by) Fulcrum Therapeutics (Subject)
| Form SC 13G/A | |
01/30/2024 8:00 PM | Fulcrum Therapeutics (Issuer) Oltmans Curtis Gale (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/30/2024 8:05 PM | Fulcrum Therapeutics (Issuer) Musso Alan A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/30/2024 8:10 PM | Fulcrum Therapeutics (Issuer) Tourangeau Greg (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/07/2023 6:02 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/07/2023 6:05 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
10/02/2023 3:01 PM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/22/2023 6:01 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/03/2023 6:05 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/03/2023 6:11 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
07/10/2023 4:06 PM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/07/2023 3:35 PM | Fulcrum Therapeutics (Subject)
| Form SC 13G/A | |
07/03/2023 3:16 PM | Fulcrum Therapeutics (Issuer) Sapir Alex (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
06/29/2023 3:16 PM | Collins James J. (Reporting) Fulcrum Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/29/2023 3:16 PM | Fulcrum Therapeutics (Issuer) Gould Robert J (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/29/2023 3:16 PM | Ezekowitz Alan (Reporting) Fulcrum Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/29/2023 3:16 PM | Dorton Katina (Reporting) Fulcrum Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/29/2023 3:16 PM | Banks Sonja (Reporting) Fulcrum Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/29/2023 3:16 PM | Fulcrum Therapeutics (Issuer) Haviland Kate (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/29/2023 3:23 PM | Fulcrum Therapeutics (Issuer) GERAGHTY JAMES A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/23/2023 4:31 PM | Fulcrum Therapeutics (Filer)
| Form 10-K/A | |
05/15/2023 6:06 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/15/2023 6:08 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
04/28/2023 3:10 PM | Fulcrum Therapeutics (Filer)
| Form DEFA14A | |
04/05/2023 7:13 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/05/2023 7:13 AM | Fulcrum Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |